J&J says IMAAVY shows sustained disease control through two years in adolescent myasthenia gravis study

PUBT · 2d ago
J&J says IMAAVY shows sustained disease control through two years in adolescent myasthenia gravis study
  • Johnson & Johnson announced new long-term data on IMAAVY for generalized myasthenia gravis, scheduled for presentation at AANEM 2026.
  • A Phase 2/3 adolescent extension study showed disease control and functional improvement held up through two years, with some steroid reduction.
  • A retrospective survey of adult treatment switches found inconsistent symptom control was the top reason to stop prior advanced therapy.
  • Clinicians reported most patients improved after moving to IMAAVY, with many also cutting prednisone use.
  • IMAAVY is positioned as an FcRn blocker with pediatric authorization in the U.S. and Europe for certain antibody-positive gMG patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609290803PR_NEWS_USPR_____NY58035) on September 29, 2026, and is solely responsible for the information contained therein.